Ceri A. Bygrave

H, Eath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial.

Journal: British journal of haematology

Published: November 24, 2025

Disparities in blood cancer survival in the UK 2009-2019: national cohort studies.

Disparities in blood cancer survival in the UK 2009-2019: national cohort studies.

Journal: BJC reports

Published: August 21, 2025

Sociodemographic Inequalities in Blood Cancer Survival in Wales.

Sociodemographic Inequalities in Blood Cancer Survival in Wales.

Journal: Studies in health technology and informatics

Published: May 17, 2025

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper.

Journal: British journal of haematology

Published: June 11, 2024

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper.

Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper.

Journal: British journal of haematology

Published: April 09, 2024

Challenges in designing and running smouldering myeloma interventional clinical trials.

Challenges in designing and running smouldering myeloma interventional clinical trials.

Journal: EJHaem

Published: February 01, 2024

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series.

Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series.

Journal: EJHaem

Published: December 13, 2023

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Journal: British journal of haematology

Published: October 15, 2023

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.

Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.

Journal: British journal of haematology

Published: December 11, 2022

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Journal: BMJ open

Published: November 17, 2022

Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.

Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.

Journal: British journal of haematology

Published: November 13, 2022

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Journal: The Lancet. Haematology

Published: July 22, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026